JP2010213710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010213710A5 JP2010213710A5 JP2010101148A JP2010101148A JP2010213710A5 JP 2010213710 A5 JP2010213710 A5 JP 2010213710A5 JP 2010101148 A JP2010101148 A JP 2010101148A JP 2010101148 A JP2010101148 A JP 2010101148A JP 2010213710 A5 JP2010213710 A5 JP 2010213710A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- seq
- administered
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 3
- 210000000214 mouth Anatomy 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000056372 ErbB-3 Receptor Human genes 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000011065 in-situ storage Methods 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- XEIVCDDCSGGZSG-UHFFFAOYSA-N 7-[3-[(3-formylphenoxy)methyl]-1,5-dimethylpyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1H-indole-2-carboxylic acid Chemical compound Cc1c(c(COc2cccc(C=O)c2)nn1C)-c1cccc2c(CCCOc3cccc4ccccc34)c([nH]c12)C(O)=O XEIVCDDCSGGZSG-UHFFFAOYSA-N 0.000 claims 1
- 241000309551 Arthraxon hispidus Species 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000000860 cochlear nerve Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003027 ear inner Anatomy 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004373 mandible Anatomy 0.000 claims 1
- 210000002050 maxilla Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000001331 nose Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 210000002741 palatine tonsil Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003681 parotid gland Anatomy 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000003635 pituitary gland Anatomy 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 150000003672 ureas Chemical class 0.000 claims 1
- 210000003708 urethra Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN02116259.X | 2002-03-26 | ||
| CNB02116259XA CN1219882C (zh) | 2002-03-18 | 2002-03-26 | 以erbb－3为基础的用于肿瘤治疗的方法和组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003578561A Division JP4660094B2 (ja) | 2002-03-26 | 2003-03-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010213710A JP2010213710A (ja) | 2010-09-30 |
| JP2010213710A5 true JP2010213710A5 (cg-RX-API-DMAC7.html) | 2011-06-16 |
| JP5249282B2 JP5249282B2 (ja) | 2013-07-31 |
Family
ID=28048642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003578561A Expired - Fee Related JP4660094B2 (ja) | 2002-03-26 | 2003-03-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
| JP2010101148A Expired - Lifetime JP5249282B2 (ja) | 2002-03-26 | 2010-04-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003578561A Expired - Fee Related JP4660094B2 (ja) | 2002-03-26 | 2003-03-26 | 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7919098B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2400021B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4660094B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN100424175C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003218600C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2480099C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003080835A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| RU2473560C2 (ru) * | 2005-11-02 | 2013-01-27 | Дьюк Юниверсити | Совместная химиотерапия и иммунотерапия |
| US20070190127A1 (en) | 2005-12-30 | 2007-08-16 | Mingdong Zhou | Extended release of neuregulin for improved cardiac function |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| DK2129396T3 (da) | 2007-02-16 | 2013-11-25 | Merrimack Pharmaceuticals Inc | Antistoffer mod ErbB3 og anvendelser deraf |
| US20090156488A1 (en) * | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| WO2009157919A1 (en) * | 2008-06-23 | 2009-12-30 | Tumor Biology Investment Group, Inc. | SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER |
| CA2732658A1 (en) * | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
| JP5743898B2 (ja) | 2008-11-28 | 2015-07-01 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | ニューレグリンペプチド及びその使用 |
| WO2010060266A1 (en) * | 2008-11-28 | 2010-06-03 | Zensun (Shanghai) Science & Technology Limited | Neuregulin and cardiac stem cells |
| PL2719708T3 (pl) | 2009-11-13 | 2018-04-30 | Daiichi Sankyo Europe Gmbh | Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3 |
| ES2571226T3 (es) | 2009-12-22 | 2016-05-24 | Roche Glycart Ag | Anticuerpos anti-HER3 y usos de los mismos |
| NZ602084A (en) | 2010-03-11 | 2014-07-25 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| IT1402149B1 (it) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2. |
| ITRM20100577A1 (it) | 2010-11-02 | 2012-05-03 | Takis Srl | Immunoterapia contro il recettore erbb-3 |
| TWI418362B (zh) * | 2010-11-19 | 2013-12-11 | Univ Nat Pingtung Sci & Tech | 溶血性巴斯德桿菌重組外膜脂蛋白e及含此之疫苗組成物 |
| US20140134170A1 (en) | 2011-03-11 | 2014-05-15 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| JP2014509593A (ja) | 2011-03-15 | 2014-04-21 | メリマック ファーマシューティカルズ インコーポレーティッド | ＥｒｂＢ経路阻害剤に対する耐性の克服 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| BR112014012539B1 (pt) | 2011-11-23 | 2022-12-20 | Medimmune, Llc | Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo |
| US9956276B2 (en) * | 2012-01-19 | 2018-05-01 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| US20170196952A1 (en) | 2014-07-07 | 2017-07-13 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| JP2017528430A (ja) * | 2014-07-17 | 2017-09-28 | ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． | 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CA2992925A1 (en) * | 2015-07-17 | 2017-01-26 | The Trustees Of The University Of Pennsylvania | Identification of immunogenic mhc class ii peptides for immune-based therapy |
| JP7014710B2 (ja) * | 2015-09-02 | 2022-02-01 | ザ クリーブランド クリニック ファウンデーション | 卵巣癌ワクチン |
| US11253580B2 (en) | 2016-01-07 | 2022-02-22 | Duke University | Cancer vaccines and methods of delivery |
| US11008402B2 (en) * | 2016-09-15 | 2021-05-18 | Universitat Stuttgart | Antigen binding protein against HER3 |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| CA3076012A1 (en) * | 2017-09-27 | 2019-04-04 | L2 Diagnostics, Llc | Erbb peptide pharmaceutical and vaccine compositions and therapeutics uses thereof for cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| DE69033842T2 (de) | 1989-08-04 | 2002-06-20 | Schering Ag | Äusserliche domäne von c-erbb-2:gp75 |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5578482A (en) | 1990-05-25 | 1996-11-26 | Georgetown University | Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses |
| DE4221256C2 (de) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenische Zusammensetzung für die topische Anwendung |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| US5741511A (en) | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
| US5888767A (en) | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
| US5941868A (en) | 1995-12-22 | 1999-08-24 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
| US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| NZ331360A (en) | 1996-03-27 | 2000-03-27 | Genentech Inc | an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex |
| EP0912734B1 (en) * | 1996-07-12 | 2010-11-03 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| KR100628846B1 (ko) | 1996-10-18 | 2006-09-29 | 제넨테크, 인크. | 항-ＥｒｂＢ２ 항체 |
| US5981201A (en) | 1997-01-08 | 1999-11-09 | Beth Israel Deaconess Medical Center | Methods of detection and treatment of breast cancer |
| JP4515542B2 (ja) | 1997-02-10 | 2010-08-04 | ジェネンテック， インコーポレイテッド | ヒレグリン変異体 |
| SE9703226D0 (sv) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
| US6197801B1 (en) | 1998-01-14 | 2001-03-06 | Usa Doctors Products, Inc. | Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| US5962274A (en) | 1998-03-13 | 1999-10-05 | Wake Forest University | Viral vector directed to predetermined target cells |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| CA2377665A1 (en) | 1999-07-06 | 2001-01-11 | General Atomics | Methods and compositions for assaying analytes |
| EP1282440A1 (en) | 2000-05-15 | 2003-02-12 | Pharmacia Italia S.p.A. | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumor agents |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| WO2006091209A2 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| DK2129396T3 (da) | 2007-02-16 | 2013-11-25 | Merrimack Pharmaceuticals Inc | Antistoffer mod ErbB3 og anvendelser deraf |
-
2003
- 2003-03-26 US US10/516,759 patent/US7919098B2/en not_active Expired - Lifetime
- 2003-03-26 EP EP11178809.7A patent/EP2400021B1/en not_active Expired - Lifetime
- 2003-03-26 CA CA2480099A patent/CA2480099C/en not_active Expired - Fee Related
- 2003-03-26 JP JP2003578561A patent/JP4660094B2/ja not_active Expired - Fee Related
- 2003-03-26 WO PCT/CN2003/000217 patent/WO2003080835A1/en not_active Ceased
- 2003-03-26 CN CNB038067625A patent/CN100424175C/zh not_active Expired - Fee Related
- 2003-03-26 EP EP03711804.9A patent/EP1495123B1/en not_active Expired - Lifetime
- 2003-03-26 AU AU2003218600A patent/AU2003218600C1/en not_active Ceased
-
2010
- 2010-04-26 JP JP2010101148A patent/JP5249282B2/ja not_active Expired - Lifetime
-
2011
- 2011-02-25 US US13/035,244 patent/US20110229478A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010213710A5 (cg-RX-API-DMAC7.html) | ||
| AU2024264558B2 (en) | Bicyclic peptide ligands specific for Nectin-4 | |
| TWI868726B (zh) | 抗體-藥物結合物之新穎製造方法 | |
| TWI712423B (zh) | 抗ｔｒｏｐ２抗體-藥物結合物之製造方法 | |
| ES2852973T3 (es) | Composiciones de receptores de antígeno quimérico | |
| ES2717911T3 (es) | Combinaciones farmacéuticas que comprenden un inhibidor de B-Raf, un inhibidor de EGFR y opcionalmente un inhibidor de PI3K-alfa | |
| JP2014526462A5 (cg-RX-API-DMAC7.html) | ||
| JP2011130770A5 (cg-RX-API-DMAC7.html) | ||
| JP2010110329A5 (cg-RX-API-DMAC7.html) | ||
| JP2013513559A5 (cg-RX-API-DMAC7.html) | ||
| JP2012509259A5 (cg-RX-API-DMAC7.html) | ||
| JP2010531140A5 (cg-RX-API-DMAC7.html) | ||
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| JP2015534577A5 (cg-RX-API-DMAC7.html) | ||
| JP2018502120A5 (cg-RX-API-DMAC7.html) | ||
| RU2014151207A (ru) | Селективность в отношении мутантных форм и комбинации соединения, представляющего собой ингибитор фосфоинозитид-3-киназы, и химиотерапевтических агентов для лечения рака | |
| US10449227B2 (en) | Conjugates for immunotherapy | |
| AU2014318545A1 (en) | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof | |
| HRP20160506T1 (hr) | Neutralizirajuće prolaktin receptorsko protutijelo mat3 i njegova terapijska uporaba | |
| JP2010529026A5 (cg-RX-API-DMAC7.html) | ||
| JP2014500862A5 (cg-RX-API-DMAC7.html) | ||
| ITRM20100577A1 (it) | Immunoterapia contro il recettore erbb-3 | |
| JP2015517523A5 (cg-RX-API-DMAC7.html) | ||
| WO2023061457A1 (zh) | 抗体药物偶联物及其用途 | |
| JP2008500277A5 (cg-RX-API-DMAC7.html) |